+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

PRINTER FRIENDLY

Wilson Disease - Pipeline Review, H2 2019

  • ID: 4901363
  • Drug Pipelines
  • December 2019
  • Region: Global
  • 59 pages
  • Global Markets Direct
1h Free Analyst Time

Speak directly to the analyst to clarify any post sales queries you may have.

1 of 3

FEATURED COMPANIES

  • Aligen Therapeutics SL
  • Deep Genomics Inc
  • DepYmed Inc
  • GMP-Orphan SA
  • LambdaGen Therapeutics
  • Vivet Therapeutics SAS
  • MORE
Wilson Disease - Pipeline Review, H2 2019

Summary

This latest Pharmaceutical and Healthcare disease pipeline guide Wilson Disease - Pipeline Review, H2 2019, provides an overview of the Wilson Disease (Genetic Disorders) pipeline landscape.

Wilson disease is a rare autosomal recessive inherited disorder of copper metabolism that is characterized by excessive deposition of copper in the liver, brain, and other tissues. Symptoms include abdominal pain, jaundice, problems with speech, swallowing and muscle stiffness. Treatment includes chelators and Vitamin E supplements.

Report Highlights

This Pharmaceutical and Healthcare latest pipeline guide Wilson Disease - Pipeline Review, H2 2019, provides comprehensive information on the therapeutics under development for Wilson Disease (Genetic Disorders), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Wilson Disease (Genetic Disorders) pipeline guide also reviews of key players involved in therapeutic development for Wilson Disease and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Phase III, Preclinical and Discovery stages are 2, 5 and 2 respectively. Similarly, the Universities portfolio in Preclinical stages comprises 1 molecules, respectively.

Wilson Disease (Genetic Disorders) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from the publisher's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope:
  • The pipeline guide provides a snapshot of the global therapeutic landscape of Wilson Disease (Genetic Disorders).
  • The pipeline guide reviews pipeline therapeutics for Wilson Disease (Genetic Disorders) by companies and universities/research institutes based on information derived from company and industry-specific sources.
  • The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
  • The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
  • The pipeline guide reviews key companies involved in Wilson Disease (Genetic Disorders) therapeutics and enlists all their major and minor projects.
  • The pipeline guide evaluates Wilson Disease (Genetic Disorders) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
  • The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
  • The pipeline guide reviews latest news related to pipeline therapeutics for Wilson Disease (Genetic Disorders)
Reasons to buy
  • Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
  • Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
  • Find and recognize significant and varied types of therapeutics under development for Wilson Disease (Genetic Disorders).
  • Classify potential new clients or partners in the target demographic.
  • Develop tactical initiatives by understanding the focus areas of leading companies.
  • Plan mergers and acquisitions meritoriously by identifying key players and it's most promising pipeline therapeutics.
  • Formulate corrective measures for pipeline projects by understanding Wilson Disease (Genetic Disorders) pipeline depth and focus of Indication therapeutics.
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
  • Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.
Note: Product cover images may vary from those shown
2 of 3

FEATURED COMPANIES

  • Aligen Therapeutics SL
  • Deep Genomics Inc
  • DepYmed Inc
  • GMP-Orphan SA
  • LambdaGen Therapeutics
  • Vivet Therapeutics SAS
  • MORE
Introduction
Report Coverage
Wilson Disease - Overview
Wilson Disease - Therapeutics Development
Pipeline Overview
Pipeline by Companies
Pipeline by Universities/Institutes
Products under Development by Companies
Products under Development by Universities/Institutes
Wilson Disease - Therapeutics Assessment
Assessment by Target
Assessment by Mechanism of Action
Assessment by Route of Administration
Assessment by Molecule Type
Wilson Disease - Companies Involved in Therapeutics Development
Alexion Pharmaceuticals Inc
Aligen Therapeutics SL
Deep Genomics Inc
DepYmed Inc
GMP-Orphan SA
Krisani Bio Sciences Pvt Ltd
LambdaGen Therapeutics
Ultragenyx Pharmaceutical Inc
Vivet Therapeutics SAS
Wilson Disease - Drug Profiles
Wilson Disease - Dormant Projects
Wilson Disease - Discontinued Products
Wilson Disease - Product Development Milestones
Appendix

List of Tables
Number of Products under Development for Wilson Disease, H2 2019
Number of Products under Development by Companies, H2 2019
Number of Products under Development by Universities/Institutes, H2 2019
Products under Development by Companies, H2 2019
Products under Development by Universities/Institutes, H2 2019
Number of Products by Stage and Target, H2 2019
Number of Products by Stage and Mechanism of Action, H2 2019
Number of Products by Stage and Route of Administration, H2 2019
Number of Products by Stage and Molecule Type, H2 2019
Wilson Disease - Pipeline by Alexion Pharmaceuticals Inc, H2 2019
Wilson Disease - Pipeline by Aligen Therapeutics SL, H2 2019
Wilson Disease - Pipeline by Deep Genomics Inc, H2 2019
Wilson Disease - Pipeline by DepYmed Inc, H2 2019
Wilson Disease - Pipeline by GMP-Orphan SA, H2 2019
Wilson Disease - Pipeline by Krisani Bio Sciences Pvt Ltd, H2 2019
Wilson Disease - Pipeline by LambdaGen Therapeutics, H2 2019
Wilson Disease - Pipeline by Ultragenyx Pharmaceutical Inc, H2 2019
Wilson Disease - Pipeline by Vivet Therapeutics SAS, H2 2019
Wilson Disease - Dormant Projects, H2 2019

List of Figures
Number of Products under Development for Wilson Disease, H2 2019
Number of Products under Development by Companies, H2 2019
Number of Products by Targets, H2 2019
Number of Products by Stage and Targets, H2 2019
Number of Products by Mechanism of Actions, H2 2019
Number of Products by Stage and Mechanism of Actions, H2 2019
Number of Products by Stage and Routes of Administration, H2 2019
Number of Products by Molecule Types, H2 2019
Number of Products by Stage and Molecule Types, H2 2019
Note: Product cover images may vary from those shown
3 of 3

Loading
LOADING...

4 of 3
  • Alexion Pharmaceuticals Inc
  • Aligen Therapeutics SL
  • Deep Genomics Inc
  • DepYmed Inc
  • GMP-Orphan SA
  • Krisani Bio Sciences Pvt Ltd
  • LambdaGen Therapeutics
  • Ultragenyx Pharmaceutical Inc
  • Vivet Therapeutics SAS
Note: Product cover images may vary from those shown
Adroll
adroll